A deal to take Seattle biotech firm Intrinsic Medication public through a SPAC merger has fallen aside.
The SPAC deal, introduced in October, would have taken the startup public through a merger with shell firm Phoenix Biotech Acquisition Corp. The merger was anticipated to boost $178.8 million.
However in an announcement Tuesday, Intrinsic Medication and Phoenix introduced that the deal was terminated.
“After cautious thought and consideration, we mutually decided that this motion is in one of the best curiosity of all events given present market circumstances,” mentioned Phoenix CEO and director Chris Ehrlich in an announcement.
Startup reached out to Intrinsic Medication for extra remark and can replace the story once we hear again.
Particular goal acquisition firms (SPACs) like Phoenix re-emerged in a giant manner through the pandemic as capital flowed to newly fashioned entities and entrepreneurs used SPACs to extra shortly enter the general public markets.
However the efficiency of post-merger SPACs has steadily dropped, significantly since January amid the bigger market downturn. Greater than 55 SPAC transactions have been referred to as off this 12 months and the standard IPO market has additionally softened.
Intrinsic Medication filed to go public in April through a conventional IPO, however withdrew its submitting in July.
In accordance with Endpoints Information’ IPO tracker, 147 biotech firms went public in 2021; 48 of these have been SPAC mergers. Up to now this 12 months, solely 25 biotech firms have gone public, 12 through a SPAC merger.
Intrinsic Medication was based in 2018 to develop sugar-based molecules matching these in human milk. Such oligosaccharides are thought to assist modulate the immune system and have an effect on the intestine microbiome, the gathering of microbes within the gut.
The SPAC merger would have fueled a part 2 medical trial testing an oligosaccharide for sufferers with irritable bowel syndrome, and supported preclinical packages for atopic dermatitis, autism spectrum dysfunction, and rheumatoid arthritis.
“Intrinsic was inspired by the optimistic suggestions from potential traders relating to the attractiveness of our novel and capital-efficient method to growing transformative new therapeutics. We stay centered on advancing these essential potential medication,” mentioned CEO and co-founder Alex Martinez within the assertion Tuesday.
In accordance with its IPO submitting in April, Intrinsic Medication had raised roughly $9.5 million in personal funding and final 12 months had $11.9 million in losses. It had eight full-time workers this March.
Co-founder Jason Ferrone, who served as chief working officer, is now normal counsel and head of company improvement at a San Diego-based pharmaceutical manufacturing firm, however continues to be a director at Intrinsic Medication, in keeping with his LinkedIn profile.